Compare CLFD & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | TRDA |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 481.6M |
| IPO Year | 1995 | 2021 |
| Metric | CLFD | TRDA |
|---|---|---|
| Price | $28.45 | $12.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $43.50 | $20.00 |
| AVG Volume (30 Days) | 63.7K | ★ 196.5K |
| Earning Date | 05-05-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,034,000.00 | $25,421,000.00 |
| Revenue This Year | $11.64 | $39.97 |
| Revenue Next Year | $22.30 | $53.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $23.78 | $4.93 |
| 52 Week High | $46.76 | $13.99 |
| Indicator | CLFD | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 55.05 |
| Support Level | $28.25 | $9.78 |
| Resistance Level | $31.22 | N/A |
| Average True Range (ATR) | 1.17 | 0.92 |
| MACD | -0.40 | 0.09 |
| Stochastic Oscillator | 4.99 | 53.40 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.